Dennis J. Ahnen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dennis J. Ahnen has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- John A. Baron
10Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina
12 shared publications Elizabeth L. Barry
6 shared publicationsHeather A. Pangburn
6 shared publicationsJudy R. Rees
6 shared publicationsLeila A. Mott
6 shared publicationsPamela L. Rice
6 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Urinary Metabolites of Prostanoids and Risk of Recurrent Colorectal Adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS)
Supplementary Table 1. Urinary PGE-M, PGI-M and dTxB2 by subject characteristics*, the Aspirin/Folate Polyp Prevention Study. Supplementary Table 2. Urinary PGE-M, PGI-M and dTxB2* by subject characteristics in the placebo group, the Aspirin/Folate Polyp Prevention Study. Supplementary Table 3. Urinary PGE-M, PGI-M and dTxB2 ratios by aspirin treatment group, the Aspirin/Folate Polyp Prevention Study. Supplementary Table 4 Urinary PGE-M, PGI-M and dTxB2 levels (ng/mg creatinine) by aspirin and folic acid treatment group, the Aspirin/Folate Polyp Prevention Study. Supplementary Table 5. Association of adenoma occurrence during study treatment with the ratios of urinary prostanoids, the Aspirin/Folate Polyp Prevention Study. Supplementary Table 6. Association adenoma occurrence during study treatment with urinary PGE-M, PGI-M and dTxB2 levels in the placebo group, the Aspirin/Folate Polyp Prevention Study. Supplementary Table 7. Association adenoma occurrence during study treatment with urinary PGE-M, PGI-M and dTxB2 levels in men, the Aspirin/Folate Polyp Prevention Study. Supplementary Table 8. Association adenoma occurrence during study treatment with urinary PGE-M, PGI-M and dTxB2 levels in women, the Aspirin/Folate Polyp Prevention Study.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Urinary Metabolites of Prostanoids and Risk of Recurrent Colorectal Adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS)
Supplementary Table 1. Urinary PGE-M, PGI-M and dTxB2 by subject characteristics*, the Aspirin/Folate Polyp Prevention Study. Supplementary Table 2. Urinary PGE-M, PGI-M and dTxB2* by subject characteristics in the placebo group, the Aspirin/Folate Polyp Prevention Study. Supplementary Table 3. Urinary PGE-M, PGI-M and dTxB2 ratios by aspirin treatment group, the Aspirin/Folate Polyp Prevention Study. Supplementary Table 4 Urinary PGE-M, PGI-M and dTxB2 levels (ng/mg creatinine) by aspirin and folic acid treatment group, the Aspirin/Folate Polyp Prevention Study. Supplementary Table 5. Association of adenoma occurrence during study treatment with the ratios of urinary prostanoids, the Aspirin/Folate Polyp Prevention Study. Supplementary Table 6. Association adenoma occurrence during study treatment with urinary PGE-M, PGI-M and dTxB2 levels in the placebo group, the Aspirin/Folate Polyp Prevention Study. Supplementary Table 7. Association adenoma occurrence during study treatment with urinary PGE-M, PGI-M and dTxB2 levels in men, the Aspirin/Folate Polyp Prevention Study. Supplementary Table 8. Association adenoma occurrence during study treatment with urinary PGE-M, PGI-M and dTxB2 levels in women, the Aspirin/Folate Polyp Prevention Study.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from No Evidence for Posttreatment Effects of Vitamin D and Calcium Supplementation on Risk of Colorectal Adenomas in a Randomized Trial
Vitamin D and calcium supplementation are postulated to have chemopreventive effects against colorectal neoplasia, yet in our previously reported randomized trial, there was no overall efficacy of calcium and/or vitamin D3 against colorectal adenoma recurrence. It is possible vitamin D3 and calcium chemopreventive effects are not detectable until beyond the 3- to 5-year follow-up captured in that trial. Accordingly, we explored possible vitamin D and calcium effects on posttreatment (observational) adenoma occurrence. In this secondary analysis of the observational follow-up phase of the Vitamin D/Calcium Polyp Prevention Study, participants who completed the treatment phase were invited to be followed for one additional surveillance colonoscopy cycle. We evaluated adenoma occurrence risk at surveillance colonoscopy, with a mean of 55 ± 15 months after treatment follow-up, according to randomized treatment with vitamin D versus no vitamin D, calcium versus no calcium, and calcium plus vitamin D versus calcium alone. Secondary outcomes included advanced and multiple adenomas. Among the 1,121 participants with observational follow-up, the relative risk (95% confidence interval, CI) of any adenoma was 1.04 (0.93–1.17) for vitamin D versus no vitamin D; 0.95 (0.84–1.08) for calcium versus no calcium; 1.07 (0.91–1.25) for calcium plus vitamin D versus calcium; and 0.96 (0.81–1.15) for calcium plus vitamin D versus neither. Risks of advanced or multiple adenomas also did not differ by treatment. Our results do not support an association between supplemental calcium and/or vitamin D3 for 3 to 5 years and risk of recurrent colorectal adenoma at an average of 4.6 years after treatment.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from No Evidence for Posttreatment Effects of Vitamin D and Calcium Supplementation on Risk of Colorectal Adenomas in a Randomized Trial
Vitamin D and calcium supplementation are postulated to have chemopreventive effects against colorectal neoplasia, yet in our previously reported randomized trial, there was no overall efficacy of calcium and/or vitamin D3 against colorectal adenoma recurrence. It is possible vitamin D3 and calcium chemopreventive effects are not detectable until beyond the 3- to 5-year follow-up captured in that trial. Accordingly, we explored possible vitamin D and calcium effects on posttreatment (observational) adenoma occurrence. In this secondary analysis of the observational follow-up phase of the Vitamin D/Calcium Polyp Prevention Study, participants who completed the treatment phase were invited to be followed for one additional surveillance colonoscopy cycle. We evaluated adenoma occurrence risk at surveillance colonoscopy, with a mean of 55 ± 15 months after treatment follow-up, according to randomized treatment with vitamin D versus no vitamin D, calcium versus no calcium, and calcium plus vitamin D versus calcium alone. Secondary outcomes included advanced and multiple adenomas. Among the 1,121 participants with observational follow-up, the relative risk (95% confidence interval, CI) of any adenoma was 1.04 (0.93–1.17) for vitamin D versus no vitamin D; 0.95 (0.84–1.08) for calcium versus no calcium; 1.07 (0.91–1.25) for calcium plus vitamin D versus calcium; and 0.96 (0.81–1.15) for calcium plus vitamin D versus neither. Risks of advanced or multiple adenomas also did not differ by treatment. Our results do not support an association between supplemental calcium and/or vitamin D3 for 3 to 5 years and risk of recurrent colorectal adenoma at an average of 4.6 years after treatment.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from No Evidence for Posttreatment Effects of Vitamin D and Calcium Supplementation on Risk of Colorectal Adenomas in a Randomized Trial
Vitamin D and calcium supplementation are postulated to have chemopreventive effects against colorectal neoplasia, yet in our previously reported randomized trial, there was no overall efficacy of calcium and/or vitamin D3 against colorectal adenoma recurrence. It is possible vitamin D3 and calcium chemopreventive effects are not detectable until beyond the 3- to 5-year follow-up captured in that trial. Accordingly, we explored possible vitamin D and calcium effects on posttreatment (observational) adenoma occurrence. In this secondary analysis of the observational follow-up phase of the Vitamin D/Calcium Polyp Prevention Study, participants who completed the treatment phase were invited to be followed for one additional surveillance colonoscopy cycle. We evaluated adenoma occurrence risk at surveillance colonoscopy, with a mean of 55 ± 15 months after treatment follow-up, according to randomized treatment with vitamin D versus no vitamin D, calcium versus no calcium, and calcium plus vitamin D versus calcium alone. Secondary outcomes included advanced and multiple adenomas. Among the 1,121 participants with observational follow-up, the relative risk (95% confidence interval, CI) of any adenoma was 1.04 (0.93–1.17) for vitamin D versus no vitamin D; 0.95 (0.84–1.08) for calcium versus no calcium; 1.07 (0.91–1.25) for calcium plus vitamin D versus calcium; and 0.96 (0.81–1.15) for calcium plus vitamin D versus neither. Risks of advanced or multiple adenomas also did not differ by treatment. Our results do not support an association between supplemental calcium and/or vitamin D3 for 3 to 5 years and risk of recurrent colorectal adenoma at an average of 4.6 years after treatment.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from No Evidence for Posttreatment Effects of Vitamin D and Calcium Supplementation on Risk of Colorectal Adenomas in a Randomized Trial
Vitamin D and calcium supplementation are postulated to have chemopreventive effects against colorectal neoplasia, yet in our previously reported randomized trial, there was no overall efficacy of calcium and/or vitamin D3 against colorectal adenoma recurrence. It is possible vitamin D3 and calcium chemopreventive effects are not detectable until beyond the 3- to 5-year follow-up captured in that trial. Accordingly, we explored possible vitamin D and calcium effects on posttreatment (observational) adenoma occurrence. In this secondary analysis of the observational follow-up phase of the Vitamin D/Calcium Polyp Prevention Study, participants who completed the treatment phase were invited to be followed for one additional surveillance colonoscopy cycle. We evaluated adenoma occurrence risk at surveillance colonoscopy, with a mean of 55 ± 15 months after treatment follow-up, according to randomized treatment with vitamin D versus no vitamin D, calcium versus no calcium, and calcium plus vitamin D versus calcium alone. Secondary outcomes included advanced and multiple adenomas. Among the 1,121 participants with observational follow-up, the relative risk (95% confidence interval, CI) of any adenoma was 1.04 (0.93–1.17) for vitamin D versus no vitamin D; 0.95 (0.84–1.08) for calcium versus no calcium; 1.07 (0.91–1.25) for calcium plus vitamin D versus calcium; and 0.96 (0.81–1.15) for calcium plus vitamin D versus neither. Risks of advanced or multiple adenomas also did not differ by treatment. Our results do not support an association between supplemental calcium and/or vitamin D3 for 3 to 5 years and risk of recurrent colorectal adenoma at an average of 4.6 years after treatment.